



AI-driven cancer prognostication

Impact potential

5/5 | Impact-generating

Net impact ratio

93% | Net impact mapped to SDGs¹

DoMore provides deep-learning outcome prediction markers that can guide oncologists to make personalized decisions regarding the need for chemotherapy after cancer surgery. Currently, ~90% of stage II and III colorectal cancer patients receive chemotherapy with no benefit, only suffering severe side effects. With DoMore, the number of patients avoiding chemotherapy could be 40%.


domorediagnostics.com

The problem

Cancer diagnostic methods may still be inaccurate and may not provide the most adapted treatment for every patient. Faulty or inaccurate cancer prognosis is an economic cost to society, and a significant human cost for individuals.

The solution

DoMore Diagnostics is on a mission to transform cancer diagnostics with artificial intelligence to improve patient care and make drug development more effective. The new method provides objective, precise prognostic information, and can guide selection of therapy to avoid over- or undertreatment.



1. Using data from the Upright Project applying Norselab's custom value mapped to the SDGs. 55% with Upright's default value set.



Good health & wellbeing


Targets 3.4 | 3.b

DoMore reduces the number of patients with uncertain prognosis and ensures precision in treatment. This also reduces the number of patients receiving unnecessarily invasive treatments with severe side effects.

Impact contribution

1 122 patients

1 122 patients for which the product tests have been validated¹.



1. This is a new KPI to better reflect the testing stage that the company is in.